Evidence map›Paper›PMID 35467249›Full record

ArticleMolecular imaging and biology2022

Hyperpolarized [1-

Shadi A Esfahani, Cody Callahan, Nicholas J Rotile, Pedram Heidari, Umar Mahmood, Peter D Caravan, Aaron K Grant, Yi-Fen Yen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. New Horizons in HyperpolarizedMolecular imaging and biology · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shadi A EsfahaniDivisionof Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, MA, Boston, USA.
Cody CallahanDepartment of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Nicholas J RotileAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Pedram HeidariDivisionof Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, MA, Boston, USA.
Umar MahmoodDivisionof Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, MA, Boston, USA.
Peter D CaravanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Aaron K GrantDepartment of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Yi-Fen YenAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. yyen1@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-9986-5327
Harvard University · USBeth Israel Deaconess Medical Center · US

Funding

Quantitative HER3 PET Imaging for Assessing Resistance and Guiding TherapyR01CA211223 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MAHMOOD, UMAR · 2018 to 2023
$1.9M
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg EffectR01CA169470 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRANT, AARON KEITH · 2013 to 2017
$1.8M
Improved methods for perfusion imaging with hyperpolarized carbon-13R01EB028824 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRANT, AARON KEITH · 2020 to 2023
$1.6M
Enhancing the therapeutic effect of receptor radionuclide therapy in neuroendocrine tumors by somatostatin receptor upregulationK08CA249047 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDARI, PEDRAM · 2020 to 2024
$1.3M
Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
MRI-Compatible PET Insert for Small Bore ScannerS10OD023503 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2017 to 2017
$600k
A Proof-of-concept of Vitamin B3 for Metabolic MR ImagingR21GM137227 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI YEN, YI-FEN · 2020 to 2021
$461k
NCI NIH HHS K08 CA249047NCI NIH HHS K08 CA259626NCI NIH HHS R01 CA169470NCI NIH HHS R01 CA211223NIBIB NIH HHS R01 EB028824NIGMS NIH HHS R21 GM137227NIH HHS S10 OD023503
6 · The paper itself

Abstract

purposeTo evaluate the use of hyperpolarized [1- PROCEDURES: Pan-TKI afatinib-sensitive NCI-N87 and resistant SNU16 human GCa cells were assessed for GLUT1, hexokinase-II (HKII), lactate dehydrogenase (LDHA), phosphorylated AKT (pAKT), and phosphorylated MAPK (pMAPK) at 0-72 h of treatment with 0.1 μM afatinib. Subcutaneous NCI-N87 tumor-bearing nude mice underwent [

resultsIn vitro analysis showed a continuous decrease in LDHA, pAKT, and pMAPK in NCI-N87 compared to SNU16 cells within 72 h of treatment with afatinib, without a significant change in GLUT1 and HKII in either cell type. [

conclusionsHP-

Indexed as

Fluorodeoxyglucose F18Stomach NeoplasmsAfatinibAnimalsGlucose Transporter Type 1HexokinaseHumansLactate DehydrogenasesLactatesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMiceMice, NudeProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktAfatinibFluorodeoxyglucose F18Glucose Transporter Type 1HexokinaseLactate DehydrogenasesLactatesProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-aktPyruvic Acid[18F]FDGGastric cancerGlycolysisHyperpolarized [1-13C]pyruvateMagnetic resonance spectroscopic imagingPETPET/MRITyrosine kinase inhibitor

Identifiers

PMID35467249
PMCPMC9588528
OpenAlexW4224434631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.